Founded in 2018, Pristyn Care operates in healthcare / health-tech (surgical care delivery). Investors last valued the company at $1.4B (post-money). No public ticker exists for the company.
3 valuations. The latest, $1.4B post-money, was set by the Series E in Jul 2025.
Tiger GlobalLEAD
Epiq CapitalLEAD
Hummingbird VenturesLEAD
Trifecta CapitalLEAD
Tiger Global ManagementLEAD
Greenoaks CapitalLEADAAngelListLEAD
Redwood TrustLEADSSequoia Capital IndiaLEADTiger GlobalEpiq CapitalHummingbird VenturesPristyn Care is a Gurugram-based health-tech company that arranges minimally invasive surgical care across specialties including proctology, gynaecology, urology and ophthalmology. Its network has grown from around 70 clinics in 2019 to more than 100 clinics and 700 partner hospitals across over 40 Indian cities today.
Founded in 2018 by Harsimarbir Singh, Dr. Vaibhav Kapoor and Dr. Garima Sawhney, the company works with a panel of more than 400 super specialist surgeons who work exclusively for Pristyn Care. In 2022 it acquired the health-tech platform Lybrate, bringing around 150 additional employees into the business.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Pristyn Care.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. Pristyn Care availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — Pristyn Care included.
No. Pristyn Care is a private company; its shares do not trade on a public exchange.
The last valuation is $1.4B (post-money, Jul 2025).
Lead investors for each round are in the funding timeline.
The closest healthcare / health-tech (surgical care delivery) peers are on the competitors page.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
